David Carl Smith
University of Michigan · 657 works · 46,497 citations · h-index 80
Top works
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- Integrative Clinical Genomics of Advanced Prostate Cancer
- Rapid ("warm") autopsy study for procurement of metastatic prostate cancer.
- Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
- Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
- Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.
- The Biology of Symbiosis
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
- Adjuvant radiotherapy and chemotherapy in breast cancer
- Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.
- Psychological support for patients undergoing breast cancer surgery: a randomised study
- Integrative clinical genomics of metastatic cancer
- Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability
- Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Full-Dose Gemcitabine in Patients With Advanced Pancreatic Cancer
- Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).
- Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).